Coherus BioSciences (CHRS) Tops Q2 EPS by 14c, beats revenue
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.37 +1.48%
EPS Growth %: +39.4%
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
ALZN, ASPU, OCCI, More
EPS Growth %: +39.4%
Financial Fact:
Income/(loss) from operations: 27.38M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.49), $0.14 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $58.7 million versus the consensus estimate of $50.47 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Standard Uranium extends private placement closing date to October 18
- Microchip Technology completes acquisition of Hailo
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
